|Other Names||M-phase inducer phosphatase 2, Dual specificity phosphatase Cdc25B, CDC25B, CDC25HU2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7256e was selected from the S353 region of human CDC25B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Directly dephosphorylates CDK1 and stimulates its kinase activity. The three isoforms seem to have a different level of activity.|
|Cellular Location||Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle pole|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CDC25B is a member of the CDC25 family of phosphatases. CDC25B activates the cyclin dependent kinase CDC2 by removing two phosphate groups and it is required for entry into mitosis. CDC25B shuttles between the nucleus and the cytoplasm due to nuclear localization and nuclear export signals. The protein is nuclear in the M and G1 phases of the cell cycle and moves to the cytoplasm during S and G2. CDC25B has oncogenic properties, although its role in tumor formation has not been determined.
Uchida, S., et al., Biochem. Biophys. Res. Commun. 316(1):226-232 (2004).Ito, Y., et al., Int. J. Mol. Med. 13(3):431-435 (2004).Wu, W., et al., Cancer Res. 63(19):6195-6199 (2003).Mils, V., et al., Exp. Cell Res. 285(1):99-106 (2003).Theis-Febvre, N., et al., Oncogene 22(2):220-232 (2003).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.